Nama

Nama Therapeutics is a biotechnology company focused on developing microbiome-based therapies for metabolic and inflammatory disorders. A spin-off from the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg, the company leverages its proprietary HuMiX platform to study the complex interactions between the human host and the gut microbiota. By identifying specific microbial biomarkers and functional pathways, Nama Therapeutics aims to engineer the gut microbiome to strengthen the mucosal barrier and mitigate diseases such as Type 2 diabetes and obesity. The company's research is grounded in the work of its founders on how dietary fiber and microbial composition influence metabolic health.